Press release Biocartis Group SA: Invitation to the

PRESS RELEASE: REGULATED INFORMATION
September 27, 2022, 07:00 CEST

Invitation to the Extraordinary Shareholders Meeting

Mechelen, Belgium, September 27 2022 Biocartis Group NV (the “Company” or “Biocartis”), an innovative molecular diagnostics company (Euronext Brussels: BCART), has the honor to invite its shareholders, holders of subscription rights, holders of convertible bonds, directors and statutory auditor to its Extraordinary General Meeting of Shareholders (“EGM”) to be held on Tuesday October 27, 2022 at 2:00 p.m. CEST at the Company’s offices at Generaal de Wittelaan 11B, 2800 Mechelen, Belgium.

At the EGM, shareholders will be asked to approve various aspects of the global recapitalization transaction which was announced by the Company on September 1, 2022. The Company believes that this transaction is an important step for the Company in order to secure the financing necessary for its future growth. which benefits all of its stakeholders and thus encourages shareholders to give the necessary consents for its implementation.

A quorum of at least 50% of the outstanding shares is required for the majority of items on the EGM agenda. All shareholders are invited to attend the meeting in order to reach the attendance quorum for these items on the agenda and to avoid the convening of a second EGM which would take place on November 14, 2022.

The majority of the proposals submitted to the EGM require approval by a majority of 75% of the votes validly cast by the shareholders. In the event that the shareholders do not approve the proposed resolutions, the recapitalization operation will not be carried out in its entirety, the Company will not be recapitalized, various costs and expenses will have to be paid by the Company, certain terms of the new convertible terms offered the loans become more restrictive and the Company will have to consider other arrangements, which may not be available on time or at all.

It is currently envisaged that the Company will be legally authorized to hold its EGM at its offices at Generaal de Wittelaan 11B, 2800 Mechelen, Belgium, and that the security holders of the Company will be authorized to physically attend the meeting as indicated in the ‘Notice of Meeting. However, the evolution of the COVID-19 pandemic is uncertain and the Belgian government could again impose measures likely to have an impact on the organization of the EGM, such as the imposition of limitations on the number of people allowed to attend gatherings. The Company will monitor the situation and potential actions in light of the COVID-19 pandemic, and may provide other relevant or impacting updates on the AGE on the Biocartis website.

To be admitted to the EGM, holders of securities issued by the Company must comply with article 7:134 of the Belgian Code of Companies and Associations and the Company’s articles of association, and complete the formalities described in the notice of summons. The notice of meeting and the other documents relating to the EGM can be consulted on the Company’s website.

— END —

More information:
Renate Degrave
Corporate Communication & Investor Relations Manager Biocartis
email [email protected]
tel +32 15 631 729
mobile +32 471 53 60 64

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next-generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis’ proprietary MDx Idylla™ platform is a fully automated real-time PCR (Polymerase Chain Reaction) system that delivers accurate and highly reliable molecular information from virtually any biological sample in virtually any environment. Biocartis develops and markets an ever-expanding menu of tests addressing key unmet clinical needs, with a focus on oncology, which represents the fastest growing segment of the MDx market globally. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as COVID-19, influenza, RSV and sepsis. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.

Biocartis and Idylla™ are registered trademarks in Europe, USA and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks belonging to Biocartis. Please refer to the product labeling for the applicable intended uses for each individual Biocartis product.
This press release is not intended for distribution, directly or indirectly, in any jurisdiction where it would be illegal. Anyone reading this press release should inform themselves about and observe these restrictions. Biocartis assumes no responsibility for any violation of these restrictions by anyone. This press release does not constitute an offer or invitation to sell or buy securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the United States Securities Act of 1933, as amended.

Forward-looking statements
Certain statements, beliefs and opinions contained in this press release are forward-looking and reflect the current expectations and projections of the Company or, if applicable, of the directors or management of the Company regarding future events such as results of operations , financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the statements. prospective. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors, including but not limited to changes in demand, competition and technology, may cause actual events, performance or results to differ materially from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. Furthermore, even if actual results or developments are consistent with the forward-looking statements contained in this press release, such results or developments may not be indicative of results or developments in future periods. No representation or warranty is made as to the accuracy or correctness of these forward-looking statements. Accordingly, the Company expressly disclaims any obligation or undertaking to issue updates or revisions to the forward-looking statements contained in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which such forward-looking statements are based, except as specifically required by law or regulation. Neither the Company, nor its advisers or representatives, nor any of its subsidiaries or the officers or employees of such persons warrant that the assumptions underlying these forward-looking statements are free from error and accept no responsibility for the future accuracy of forward-looking statements. statements contained in this press release or the actual occurrence of anticipated developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Comments are closed.